OBJECTIVES: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available biosimilars in the European Union (EU). METHODS: A three-step process was established to identify key drivers for the uptake of biosimilars in top ten EU Member States (MS) pharmaceutical markets (Belgium, France, Germany, Greece, Hungary, Italy, Poland, Spain, Sweden and UK): 1) Literature review to identify incentive policies in place to enhance biosimilars adoption; 2) Assessment of biosimilar market dynamics based on database analysis; 3) Regression model analysis on price using the following explicative variables: incentive policies, price difference between the biosimilar and the originator product, distribution channel, generic uptake and generic price cut, pharmaceutical expenditure per capita and market competition. RESULTS: At study cut-off date, 20 biosimilars were available on the market. Incentive policies applied to biosimilars were found to be heterogeneous across countries and uptakes of biosimilars were also very heterogeneous between different therapeutic classes and countries. Results from the model demonstrated that incentive policies and date of first biosimilar market entry were correlated to biosimilar uptake. Pharmaceutical expenditure per capita and the highest generic uptake were inversely correlated with biosimilar uptake. Average generic price discount over originator, and the number of biosimilars showed a trend toward statistical significance for correlation with biosimilar uptake but did not reach the significance threshold. Biosimilar price discount over original biologic price, number of analogues, and distribution channel were not correlated with the biosimilar uptake. CONCLUSIONS: Understanding drivers of biosimilars uptake becomes a critical issue to inform policy decision makers. This study showed that incentive policies to enhance uptake remain an important driver of biosimilar penetration while biosimilar price discounts have no impact. Future research is warranted when the biosimilar market gains maturity.